Moherndran Archary

King Edward VIII Hospital — South Africa

Medicine · Health Sciences

28h-index3.2kcitations158works1.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV/AIDS Research and Interventions(70), HIV Research and Treatment(38), HIV/AIDS drug development and treatment(37), HIV-related health complications and treatments(18), Child Nutrition and Water Access(16)

Publications154 total

Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa
Contemporary Clinical Trials·2026Open Access
The mysterious joint: Septic arthritis and acute osteomyelitis due to Fusarium species in a child with type II Chiari malformation
South African Medical Journal·2025Open Access
Dolutegravir in neonates: finally we are getting there!
The Lancet HIV·2025
Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial
EBioMedicine·2025· 1 citedOpen Access
Impact of chlorhexidine and emollient cleansing on bloodstream infections in a Neonatal ICU
Southern African Journal of Infectious Diseases·2025Open Access
Pharmacokinetics of long‐acting cabotegravir and rilpivirine in virologically suppressed adolescents living with HIV‐1 in Sub‐Saharan Africa: Data from the LATA trial
British Journal of Clinical Pharmacology·2025Open Access
Adolescents in phase 3 HIV clinical trials
The Lancet Child & Adolescent Health·2025
BREATHER Plus clinical trial design: A randomised non-inferiority trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily ART in virologically suppressed adolescents living with HIV aged 12 to <20 years in sub-Saharan Africa
Contemporary Clinical Trials·2025· 1 citedOpen Access
Living in the shadows: the persistence of secrecy in young people living with HIV on antiretroviral therapy, a qualitative study of the BREATHER Plus trial
SSM - Qualitative Research in Health·2025· 1 citedOpen Access
Pharmacokinetics and safety of dolutegravir in children receiving rifampicin tuberculosis treatment in South Africa (ORCHID): a prospective cohort study
The Lancet HIV·2025· 2 cited
Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial
The Lancet HIV·2025· 8 citedOpen Access
Author Correction: Sustained aviremia despite anti-retroviral therapy non-adherence in male children after in utero HIV transmission
Nature Medicine·2025Open Access
Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): a randomised, open-label, non-inferiority, 96-week trialevaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen (CAB/RPV) compared to daily oral therapy (DTG based TDF or TAF with 3TC or FTC backbone) in virologically suppressed adolescents living with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa
SSRN Electronic Journal·2025Open Access
Short-Cycle Therapy (Weekends-Off) on Dolutegravir-Based Antiretroviral Therapy in Adolescents Living with HIV (BREATHER Plus): A Randomised, Open-Label, 96-Week Non-Inferiority Trial
SSRN Electronic Journal·2025Open Access
BREATHER Plus Clinical Trial Design: A Randomised Non-Inferiority Trial Evaluating the Efficacy, Safety and Acceptability of Short Cycle (Five Days on, Two Days Off) Dolutegravir/Tenofovir-Based Triple Antiretroviral Therapy (Art) Compared to Daily Art in Virologically Suppressed Adolescents Living with HIV Aged 12 to <20 Years in Sub-Saharan Africa
SSRN Electronic Journal·2025Open Access
Weight Gain, Body Composition and Metabolic Parameters on Dolutegravir-Based Antiretroviral Therapy Versus Standard of Care in Children and Adolescents: A Secondary Analysis of the ODYSSEY Trial
SSRN Electronic Journal·2025Open Access
Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M <sup>TM</sup> adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial
Human Vaccines & Immunotherapeutics·2024· 2 citedOpen Access
Impact of age on antimicrobial prescriptions in hospitalized children at three academic centres in South Africa: a point prevalence survey
Journal of Tropical Pediatrics·2024
Treatment of HIV Infection in Children Across the Age Spectrum
Clinics in Perinatology·2024· 1 cited
Changes in the medical admissions and mortality amongst children in four South African hospitals following the COVID-19 pandemic: A five-year review
PLOS Global Public Health·2024Open Access
page 1 of 8Next →

Frequent Co-authors

Elaine J. Abrams(12), Tim R. Cressey(11), Pablo Rojo(11), Anna Turkova(9), Angela Colbers(9), Martina Penazzato(9), Thumbi Ndung’u(9), David M. Burger(9), Brian C. Zanoni(8), Jessica E. Haberer(8), Philip Goulder(8), Victor Musiime(7), Theodore Ruel(7), Thobekile Sibaya(7), Pauline Amuge(6), Carlo Giaquinto(6), Diana M. Gibb(6), Natella Rakhmanina(6), Nandita Sugandhi(6), Edmund V. Capparelli(6)